Abbott Laboratories (ABT) Tops Q3 EPS by 2c; Narrows FY12 EPS Outlook
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Price: $108.33 -0.42%
Revenue Growth %: +14.2%
Financial Fact:
Interest expense: 117M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +14.2%
Financial Fact:
Interest expense: 117M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Abbott Laboratories (NYSE: ABT) reported Q3 EPS of $1.30, $0.02 better than the analyst estimate of $1.28. Revenue for the quarter came in at $9.77 billion versus the consensus estimate of $9.93 billion.
Abbott Laboratories sees FY2012 EPS of $5.06-5.08, versus prior guidance of $5.00-5.10 and the consensus of $5.06.
For earnings history and earnings-related data on Abbott Laboratories (ABT) click here.
Abbott Laboratories sees FY2012 EPS of $5.06-5.08, versus prior guidance of $5.00-5.10 and the consensus of $5.06.
For earnings history and earnings-related data on Abbott Laboratories (ABT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
